At the first consultation the GPs registered symptoms, results of otoscopy and tympanometry, together with diagnosis and treatment. The children were followed up four weeks later.
Results: VX-765 cell line Sleep problems at inclusion are statistically significant associated with having one or more symptom after four weeks in children between 0 and 2 years (OR: 2.02 (95% confidence interval (CI): 1.24-3.31)). If the result of tympanometry is a flat curve, the OR for being referred is 3.24 (CI: 1.61-6.55) in children between 0 and 2 years compared to children without a flat curve. The OR for being referred in children between 2 and 7 years with a flat curve is 8.94
(CI: 4.18-19.11) when compared to children without a flat curve.
Conclusion: Sleep problems at inclusion were the only symptom statistically significant associated with having one or more symptoms after four weeks in children between 0 and 2 years. (C) 2012 Elsevier Ireland Ltd. All rights reserved.”
“”"Alternatives for
the Treatment of Schistosomiasis: Physico-Chemical Characterization of an Inclusion Complex Between Praziquantel and Hydroxypropyl-beta-Cyclodextrin”". Praziquantel (PZQ) is the drug of choice commonly used for the treatment BAY 1895344 of shistosomiasis. However, it has low aqueous solubility, which could limit its bioavailability in the body. To circumvent these features, an inclusion complex with hydroxypropyl-beta-cyclodextrin (HP-beta-CD) was prepared. Thus, the objective of this work was to prepare and characterize the PZQ/HP-beta-CD AZD4547 order inclusion complex. Morphological, spectroscopic, and calorimetric analysis showed the first signs of the guest/host interaction. The complexation kinetic analysis was used to determine
the kinetic constant and, besides that, it was possible to establish the time consumed to reach equilibrium. Using the solubility isotherm, it was observed that the interaction with HP-beta-CD increased 2.4 fold the aqueous solubility of plain PZQ. In vitro cytotoxicity tests, using fibroblast cells, evidenced no toxicity for these cells at the concentrations tested. These results demonstrated that there is a potential use of PZQ in formulations with HP-beta-CD.”
“Objectives: Cochlear implantation is a well established treatment method in severe to profound hearing impaired people. Hearing devices do not cure hearing loss, but correct the disability, so it is important to assess the benefits not only on auditory-verbal performances but in terms of health-related quality of life.
Materials and methods: We evaluated the health-related quality of life in a cochlear implant group (84 patients), split into two subgroups, according to the age of implantation and compared with a hearing aided group (50 patients). We used the Nijmegen cochlear implant HRQoL questionnaire which was sent to the parents.